全球竞赛已打响，关注云顶新耀和石药集团

Core Insights - The report maintains a strong market rating for the biopharmaceutical industry, particularly focusing on in vivo CAR-T therapies, highlighting the competitive landscape and potential investment opportunities in companies like Cloudbreak and CSPC [1][2] - In vivo CAR-T therapies are expected to revolutionize cell therapy paradigms, with several biotech firms, including Capstan Therapeutics and EsoBiotec, initiating clinical trials [2][31] - The global sales of autologous CAR-T therapies are projected to exceed $4.5 billion in 2024, with significant growth potential despite challenges such as complex manufacturing processes and high costs [11][12] In Vivo CAR-T Therapy - In vivo CAR-T therapy simplifies the manufacturing process and reduces costs, potentially making treatments more accessible and affordable compared to traditional methods [20][21] - The core challenge lies in the effective and safe delivery of CAR constructs to target T cells, with two main technological routes: lentiviral vectors and RNA delivery systems [31][28] - Companies like AstraZeneca and AbbVie are actively investing in in vivo CAR-T platforms, indicating a strong interest from major pharmaceutical players [30][29] Market Trends and Strategies - The report identifies key investment strategies, recommending a focus on leading companies and those with promising clinical data, particularly in the context of upcoming industry catalysts [2][59] - Notable companies to watch include BeiGene, Innovent Biologics, and CSPC, which are expected to drive growth through innovative drug development and commercialization efforts [2][61] - The report emphasizes the importance of clinical data and commercialization as key drivers for the success of innovative drugs in the market [2][59] Company Highlights - Cloudbreak has developed a fully integrated mRNA platform with clinical validation, focusing on multiple cancer and autoimmune-related mRNA therapeutics [50][54] - CSPC's SYS6020, an mRNA-LNP based CAR-T therapy, has entered clinical trials, showcasing advancements in safety and efficacy compared to traditional CAR-T products [56][58] - Capstan Therapeutics has reported promising preclinical data for its mRNA-based in vivo CAR-T therapies, indicating strong potential for future clinical applications [44][49]